GlassScriptPhysician profile
Michael J Richardson
NPI 1477589422
$3,946.04
in general payments reported to CMS, 2019-2025
37 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $319 · 2021: $584 · 2022: $489 · 2023: $669 · 2024: $819 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.21 | 2021-2025 | |
| Novo Nordisk INC | $390.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $282.50 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $251.17 | 2021-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $195.78 | 2019-2025 | Arexvy, Shingrix, Boostrix |
| Amgen INC. | $175.44 | 2019-2024 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $168.32 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $147.65 | 2019-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.68 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $135.05 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $99.17 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.51 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $79.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $74.65 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.69 | 2022-2024 | Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.